CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

As previously disclosed by CareDx, Inc. (the “Company”) on its Notification of Late Filing on Form 12b-25 (the “Form 12b-25”) filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2017, the Company was unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for its fiscal year ended December 31, 2016 (the “Form 10-K”). to SEC regulations, upon filing the Form 12b-25, the Company had until April 17, 2017 to timely file the Form 10-K. However, the Company was unable to file the Form 10-K by the extended filing date, as it requires additional time to complete the disclosures in the Form 10-K. The Company intends to file the Form 10-K as promptly as possible, but no assurances can be given as to the definitive date on which the Form 10-K will be filed.

The information contained in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

About CAREDX, INC. (NASDAQ:CDNA)

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

CAREDX, INC. (NASDAQ:CDNA) Recent Trading Information

CAREDX, INC. (NASDAQ:CDNA) closed its last trading session down -0.10 at 1.05 with 141,885 shares trading hands.